<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471497</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2303</org_study_id>
    <secondary_id>2007-000208-34</secondary_id>
    <nct_id>NCT00471497</nct_id>
  </id_info>
  <brief_title>A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</brief_title>
  <acronym>ENESTnd</acronym>
  <official_title>A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg
      twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients
      with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase
      (CML-CP).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2007</start_date>
  <completion_date type="Anticipated">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">September 2, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular Response Rate (MMR) at 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Rate of MMR is defined as &lt;= 0.1% BCR-ABL/ABL ratio by international scale (IS), measured by real-time quantitative polymerase chain reaction (RQ-PCR) which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson protooncogene)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Durable MMR at 24 Months.</measure>
    <time_frame>Baseline, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate Reduction in BCR-ABL Transcript Levels in Nilotinib Treatment Arms With Imatinib at 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">852</enrollment>
  <condition>Myelogenous Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>nilotinib 300mg bid (investigating arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinb 400 mg bid (investigating arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>imatinib 400mg QD (control arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.</description>
    <arm_group_label>nilotinib 300mg bid (investigating arm)</arm_group_label>
    <arm_group_label>Nilotinb 400 mg bid (investigating arm)</arm_group_label>
    <other_name>AMN107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <description>Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).</description>
    <arm_group_label>imatinib 400mg QD (control arm)</arm_group_label>
    <other_name>STI571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chronic myelogenous leukemia in chronic phase patients within the first 6 months of
             diagnosis.

          -  Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of
             Philadelphia chromosome

        Exclusion criteria:

          -  Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except
             for no more than 2 weeks in duration of imatinib

          -  Any medical treatment for CML prior to study entry for longer than 2 weeks with the
             exception of hydroxyurea and/or anagrelide

          -  Uncontrolled or significant cardiovascular disease.

          -  Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or
             uncontrolled infection).

          -  Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)

          -  Currently taking certain medications that could affect the rhythm of your heart.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles Dept. of Hematology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Southern Dept of Kaiser South 3</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Southern Dept of Kaiser South 9</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Southern San Diego Zion Avenue</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Northern Kaiser Med</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Northern Vallejo Med Center/Med Offices</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers RMCC - Colorado Springs</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Dept. FloridaCancerSpecialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties Research Dept.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida PA Cancer Centers of FL</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Institute Flordia Cancer Affilates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center Section of Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Institute Dept. of Indiana Blood&amp;Marrow</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&amp;Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Center KCCC Business Office</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University / Breslin Cancer Center Breslin Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cancer Associates Dept. of Boone Hospital Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Department of Research</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Clinical Trials Office</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina UNC Lineberger Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of North Carolina Cancer Centers of NC-Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Dept. of Industry Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati / Barrett Cancer Center Dept.of Internal Med.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation CCF</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists Compass Oncology -BKM</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas CC of C -Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Dept. of Centennial Medical</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center ( Medical City Dallas Hospital)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas / HOAST CCC of So.TX- Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1902AVG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70330-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaú</city>
        <state>SP</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01224-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01401-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <zip>110111</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <state>CZE</state>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen</city>
        <state>Cedex</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <state>Loire</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers Cedex 1</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes</city>
        <zip>35019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima city</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nishinomiya-city</city>
        <state>Hyogo</state>
        <zip>663 8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tsukuba-city</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa-city</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tsu-city</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagasaki-city</city>
        <state>Nagasaki</state>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hidaka-city</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama-city</city>
        <state>Saitama</state>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamamatsu-city</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niigata</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Selangor</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40032</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1099 - 023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0027</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lulea</city>
        <zip>SE-971 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sundsvall</city>
        <zip>SE-851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Kou</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow - Scotland</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1010</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.cmlclinicaltrials.com</url>
    <description>Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <results_first_submitted>April 10, 2013</results_first_submitted>
  <results_first_submitted_qc>June 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2013</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>bone marrow</keyword>
  <keyword>leukemia symptoms</keyword>
  <keyword>lukemia</keyword>
  <keyword>cml</keyword>
  <keyword>complete blood count</keyword>
  <keyword>lymphocyte</keyword>
  <keyword>blood cancer</keyword>
  <keyword>leukocytes</keyword>
  <keyword>chronic leukemia</keyword>
  <keyword>bone marrow biopsy</keyword>
  <keyword>leukemia research</keyword>
  <keyword>leukemia cells</keyword>
  <keyword>bone marrow disease</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>blood cancer symptoms</keyword>
  <keyword>white blood cell diseases</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>leukemia treatment</keyword>
  <keyword>leukemia facts</keyword>
  <keyword>leucemia</keyword>
  <keyword>facts about leukemia</keyword>
  <keyword>myelogenous leukemia</keyword>
  <keyword>newly diagnosed CML</keyword>
  <keyword>newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Not Completed Study means that the patient discontinued from the study by study day 294 (data cut-off).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Imatinib 400 mg QD</title>
          <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated.</description>
        </group>
        <group group_id="P2">
          <title>Nilotinb 300 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="P3">
          <title>Nilotinib 400 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="282"/>
                <participants group_id="P3" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SAFETY ANALYSIS SET</title>
              <participants_list>
                <participants group_id="P1" count="280">Safety set contained patients who received at least one dose of study medication.</participants>
                <participants group_id="P2" count="279">Safety set contained patients who received at least one dose of study medication.</participants>
                <participants group_id="P3" count="277">Safety set contained patients who received at least one dose of study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="237">Completed means patient is on treatment in core phase of the study (ongoing) by data cut-off.</participants>
                <participants group_id="P2" count="247">Completed means patient is on treatment in core phase of the study (ongoing) by data cut-off.</participants>
                <participants group_id="P3" count="241">Completed means patient is on treatment in core phase of the study (ongoing) by data cut-off.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Value</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sub optimal response or treat. failure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients in the Full Analysis Set (FAS) were analyzed according to the treatment they were randomized to regardless of actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>Imatinib 400 mg QD</title>
          <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated.</description>
        </group>
        <group group_id="B2">
          <title>Nilotinb 300 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="B3">
          <title>Nilotinib 400 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="283"/>
            <count group_id="B2" value="282"/>
            <count group_id="B3" value="281"/>
            <count group_id="B4" value="846"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="14.34"/>
                    <measurement group_id="B2" value="67" spread="14.53"/>
                    <measurement group_id="B3" value="65" spread="13.90"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 35 - &lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=45 - &lt;55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=55 - &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Molecular Response Rate (MMR) at 12 Months</title>
        <description>Rate of MMR is defined as &lt;= 0.1% BCR-ABL/ABL ratio by international scale (IS), measured by real-time quantitative polymerase chain reaction (RQ-PCR) which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson protooncogene)</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Patients in the Full Analysis Set (FAS) were analyzed according to the treatment they were randomized to regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Molecular Response Rate (MMR) at 12 Months</title>
          <description>Rate of MMR is defined as &lt;= 0.1% BCR-ABL/ABL ratio by international scale (IS), measured by real-time quantitative polymerase chain reaction (RQ-PCR) which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson protooncogene)</description>
          <population>Patients in the Full Analysis Set (FAS) were analyzed according to the treatment they were randomized to regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="17.6" upper_limit="27.6"/>
                    <measurement group_id="O2" value="44.3" lower_limit="38.4" upper_limit="50.3"/>
                    <measurement group_id="O3" value="42.7" lower_limit="36.8" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Durable MMR at 24 Months.</title>
        <time_frame>Baseline, 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate Reduction in BCR-ABL Transcript Levels in Nilotinib Treatment Arms With Imatinib at 12 Months</title>
        <time_frame>Baseline, 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months</title>
        <time_frame>Baseline, 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety set contained patients who received at least one dose of study medication. Patients were summarized according to the safety treatment allocation (the treatment they actually received first).</desc>
      <group_list>
        <group group_id="E1">
          <title>Imatinib 400 mg QD</title>
          <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated.</description>
        </group>
        <group group_id="E2">
          <title>Nilotinib 300 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="E3">
          <title>Nilotinib 400 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Brugada syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Trisomy 8</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Faecal vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatic fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Traumatic renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blast cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardioactive drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Benign uterine neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blast crisis in myelogenous leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Colon cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Leukaemic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Paraproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basilar artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Retained products of conception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="275" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="272" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

